Adverse effects after Sermorelin administration may include local injection reaction, nausea, and facial flushing
Abstract Background In idiopathic intracranial hypertension (IIH), sustained weight loss is the main pillar in modifying disease course, whereby glucagon-like peptide-1 receptor agonists (GLP-1-RAs) could present an attractive treatment option
Most protocols start at 0.51 mL (50100 units) SQ or IM, 13 times per week, titrated up to 2 mL depending on tolerance and goals
The molecules, indications, and practical requirements differ enough that conflating them does a disservice to patients who need clear guidance
Insurance providers may reimburse patients with a prescription for the labelled use, which may require prior authorization